A. Van Oosterom
- Oncology top 10%
- Cancer Treatment and Pharmacology 4
- Colorectal Cancer Treatments and Studies 3
- Hematology top 10%
-
- Sarcoma Diagnosis and Treatment 7
- Renal cell carcinoma treatment 3
-
- Cancer therapeutics and mechanisms 4
-
- Testicular diseases and treatments 4
-
- Cardiac tumors and thrombi 3
-
- Lymphoma Diagnosis and Treatment 3
- Co-authors
- Maria Dêbiec‐RychterGuy DebrockRaymond OyenRaf SciotJaap VerweijPHM de MulderYves HumbletE. Van Marck
- Cited by
- OncologyCancer ResearchHematology
- Partner nations
- BelgiumNetherlandsItaly
In The Last Decade
A. Van Oosterom
27 papers receiving 549 citations
Peers
Comparison fields: 5 of 72
- Oncology 268
- Cancer Research 124
- Hematology 75
- Pulmonary and Respiratory Medicine 209
- Molecular Biology 228
Countries citing papers authored by A. Van Oosterom
This map shows the geographic impact of A. Van Oosterom's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Van Oosterom with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Van Oosterom more than expected).
Fields of papers citing papers by A. Van Oosterom
This network shows the impact of papers produced by A. Van Oosterom. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Van Oosterom. The network helps show where A. Van Oosterom may publish in the future.
Co-authorship network
The 25 scholars most cited alongside A. Van Oosterom, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Combined analysis of the EORTC and SWOG phase II trials of imatinib in advanced dermatofibrosarcoma protuberans (DFSP) | 2009 | 3 |
| 2 | 2006 | 7 | |
| 3 | Combined anti-EGFR blockade: A phase I pharmacokinetic and molecular pharmacodynamic study of Cetuximab (Erbitux (R)) and Gefitinib (Iressa (R)) in patients with advanced colorectal, head and neck and non-small cell lung cancer expressing the EGFR | 2005 | 4 |
| 4 | 2003 | 1 | |
| 5 | 2003 | 131 | |
| 6 | 2002 | 22 | |
| 7 | Chordoma of the mediastinum. | 1999 | 4 |
| 8 | 1998 | 13 | |
| 9 | 1998 | 26 | |
| 10 | 1998 | 41 | |
| 11 | 1997 | 16 | |
| 12 | 1996 | 8 | |
| 13 | 1995 | 46 | |
| 14 | 1995 | 67 | |
| 15 | 1995 | 72 | |
| 16 | 1994 | 0 | |
| 17 | 1993 | 6 | |
| 18 | 1993 | 5 | |
| 19 | 1991 | 33 | |
| 20 | 1991 | 2 |
About A. Van Oosterom
A. Van Oosterom is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Toxicology, having authored 28 papers that have together received 572 indexed citations. Recurring topics across this work include Sarcoma Diagnosis and Treatment (7 papers), Testicular diseases and treatments (4 papers), Cancer Treatment and Pharmacology (4 papers), Cancer therapeutics and mechanisms (4 papers), Renal cell carcinoma treatment (3 papers), Cardiac tumors and thrombi (3 papers), Colorectal Cancer Treatments and Studies (3 papers) and Lymphoma Diagnosis and Treatment (3 papers). The work is most often cited by research in Oncology (268 citations), Cancer Research (124 citations) and Hematology (75 citations). A. Van Oosterom has collaborated with scholars based in Belgium, Netherlands and Italy. Frequent co-authors include Maria Dêbiec‐Rychter, Guy Debrock, Raymond Oyen, Raf Sciot, Jaap Verweij, PHM de Mulder, Yves Humblet, E. Van Marck, Martine Berlière and Véronique D’Hondt. Their work appears in journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.